Exposure to TNF inhibitors was linked to a reduced risk for cardiovascular events among patients with AS; the impact of IL-17 inhibitors was less clear.

Figure 1. Schematic illustration of NLRP3 inflammasome pathway and potential blockade sites of various pharmacological inhibitors. The signal 1 or the priming signal is mediated by pathogenic PAMPs ...

The study revealed that younger patients (16-24 years) with moderate-to-severe psoriasis were more likely to discontinue TNF ...

Age at initiation of treatment and the type of biologic therapy prescribed effect the rate of drug survival among patients with psoriasis.

In addition, several antibodies, including risankizumab, brazikumab, mirikizumab and guselkumab, recognize the IL-23p19 subunit and are being evaluated in clinical trials in patients with Crohn’s ...

Dice’s lead product candidate is oral IL-17 inhibitor DC-806, which is in phase 2 testing as a treatment for plaque psoriasis. If it makes it through development, DC-806 could offer a more ...

Children with rheumatic diseases may face increased risks for COVID-19-related hospitalization, particularly those using glucocorticoids, rituximab, or mycophenolate.

Objectives Interleukin (IL)-17 signalling has been shown to be a key regulator of disease in ankylosing spondylitis (AS) with several IL-17 blockers currently clinically approved. Despite this, the ...

CAR T-Cell therapy market growth is propelled by revolutionary results in treating certain blood cancers.New Delhi, Feb. 07, 2025 (GLOBE NEWSWIRE) -- The global CAR T-cell therapy market valuation is ...

Notable advancements in 2023 include developments in uricase therapy, new xanthine oxidase inhibitors ... for IL-6 blockade in polymyalgia rheumatica and of secukinumab for IL-17 blockade in ...

Equillium, Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and ...